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ttp://dx.doi.org/10.1016/j.ajpath.2013.03.004Patients undergoing glucocorticoid therapy for a variety of disorders, including autoimmune diseases
and hematological malignancies, are at risk of developing osteonecrosis. Despite extensive research in
both patients and animal models, the underlying pathogenesis remains unclear. Proposed inciting
mechanisms include intravascular thrombotic occlusion, marrow fat hypertrophy, osteocyte and/or
endothelial cell apoptosis, hypercoagulability, and vasoconstriction of speciﬁc arteries and arterioles
supplying bone. Our laboratory has developed a model of steroid-induced osteonecrosis in BALBcJ mice
which reﬂects clinically relevant exposures to glucocorticoids in which treated mice develop osteo-
necrosis of the distal femoral epiphysis when administered 4 to 8 mg/L dexamethasone in drinking water
for 6 weeks. We identiﬁed lesions in arterioles supplying this area, with the mildest occurring in knees
without any evidence of osteonecrosis. However, arteriopathy was more common among mice that did
versus did not develop osteonecrosis (P < 0.0001); in mice with osteonecrosis, the associated vessels
showed transmural necrosis and thickening of the vessel wall progressing to the point of luminal
obstruction. In the most severe cases of osteonecrosis, end-stage lesions consisted of fully occluded
vessels with marrow and bone necrosis involving the entire epiphysis. We propose that a primary
arteriopathy is the initiating event in the genesis of steroid-induced osteonecrosis and provides a basis
for future investigation of this disease process. (Am J Pathol 2013, 183: 19e25; http://dx.doi.org/
10.1016/j.ajpath.2013.03.004)Supported by the National Cancer Institute grants CA 142665 and CA
21765 and by the American Lebanese Syrian Associated Charities
(ALSAC).
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TX.The association between corticosteroid use and osteonec-
rosis (ON) was ﬁrst described in patients receiving
renal transplant who were undergoing immunoablation
or immunosuppression as part of their transplantation
regimen.1 Glucocorticoids are used extensively to treat
diverse diseases such as rheumatoid arthritis, asthma, and
lymphoid malignancies. The incidence of ON is as high as
37% in patients with systemic lupus erythematosus,2 and
a recent prospective magnetic resonance image screening of
children being treated for acute lymphoblastic leukemia
showed an 18% incidence of symptomatic ON and a 72%
incidence of magnetic resonance image-detectable ON.3
No consensus is widely held as to the pathogenesis of
corticosteroid-induced ON. It is generally agreed that the
end point is the interruption of blood supply to the bone,
leading to death of osteocytes and adipocytes with resultant
bone marrow edema and, ultimately, destruction of the
architecture of the bone.4 Proposed inciting mechanismsstigative Pathology.
.include intravascular thrombotic occlusion, extravascular
adipogenesis/fat hypertrophy, osteocyte and/or endothelial
cell apoptosis, hypercoagulability, and vasoconstriction of
arteries and arterioles that supply the bone.5
Our laboratory has developed a model of steroid-induced
ON in BALBcJ mice which reﬂects clinically relevant ex-
posures to glucocorticoids.6 The administration of dexa-
methasone (DEX) in the drinking water at 4 mg/L in the
ﬁrst week of treatment and 2 mg/L for the remainder of
a 12-week treatment resulted in a 40% incidence of ON
of the distal femoral epiphysis. This mouse model was de-
veloped to test the inﬂuence of various chemotherapeutic
Janke et aldrug combinations and treatment schedules, as well as
speciﬁc gene-related effects, on the development of ON.
In the present study, we investigated the pathogenesis of
DEX-induced ON in BALB/c mice by careful examination
and comparison of sequential histological sections of




DEX sodium phosphate solution was purchased from
American Pharmaceutical Partners, Inc. (Schaumburg, IL).
Escherichia coli-asparaginase was obtained from Ovation
Pharmaceuticals (Deerﬁeld, IL); 6-mercaptopurine was ob-
tained from Acros Organics (Fair Lawn, NJ). Sulfame-
thoxazole and trimethoprim oral suspension was obtained
from Hi-Tech Pharmacal Co., Inc. (Amityville, NY), and
tetracycline was purchased from Sigma (St. Louis, MO).
The folic acidedeﬁcient diet for mice was obtained from
TestDiet (Richmond, IN).
Treatment Regimens
The tissues evaluated for this study were obtained from mice
used in a variety of pilot experiments that were performed to
explore the effects of possible risk factors for DEX-induced
ON, such as age, duration, and dose of treatment with DEX,
and the effect of various chemotherapeutic agents used in
combination with DEX. Male BALB/c mice were used in all
experiments because previous studies showed this strain to be
most susceptible to DEX-induced ON, with male mice
showing a higher incidence than female mice.6 Herein, we
used two substrains of BALB/c mice: BALBcJ (Jackson
Laboratories, Sacramento, CA) and BALBcAnN (Harlan
Laboratories, Houston, TX). These two substrains have been
reported to have different susceptibility to DEX-induced
adverse effects.7 Treatment started at postnatal days 24 to
28 and lasted for 6 weeks. DEX (4 mg/L or 8 mg/L) and
6-mercaptopurine (2 mg/L or 4 mg/L) were administered in
the drinking water, whereas asparaginase was administered
by intraperitoneal injections at 7500 IU/kg once or twice
weekly. To prevent opportunistic infections, 1000 mg/L
tetracycline, 7 days a week, and 600 mg/L and 120 mg/L,
respectively, sulfamethoxazole and trimethoprim oral
suspension 3.5 days a week were also added to drinking
water. Mice were fed a folic acidedeﬁcient diet that con-
tained <0.05 ppm folic acid during treatment; this diet
was used previously in developing the murine model of
glucocorticoid-induced ON.6 All experiments involving the
production and use of mice were approved by the Institutional
Animal Care and Use Committee of St. Jude Children’s
Research Hospital. The treatment protocols and number of
mice evaluated after treatment with DEX with or without
asparaginase or 6-mercaptopurine are outlined in Table 1.20Histopathology
At necropsy, both hind limbs were collected, ﬁxed in 10%
formalin, decalciﬁed in 10% formic acid, routinely pro-
cessed, sagittally sectioned, and stained with H&E. Sections
were evaluated for the presence of ON. Also documented at
that time was the presence or absence of evaluable arteriolar
branches of the medial genicular artery located along the
surface of the distal femoral condyles. Mice with ON or
arteriolar lesions in one or both legs were classiﬁed as ON
positive or arteriopathy positive, respectively. Elastic stains
(kit AR163; Dako, Carpinteria, CA) were performed on
sections previously stained with H&E after removal of the
coverslip and de-staining.
Immunohistochemistry
For immunohistochemistry, 4- to 6-mm serial sections were
ﬁrst deparafﬁnized in xylene and then rehydrated through
graded alcohols. Endogenous peroxidases were blocked by
incubating slides for 5 minutes with 3% aqueous hydrogen
peroxide. Primary antibodies used in this study included
CD31 (catalog #553370; Pharmingen, San Diego, CA) and
a-smooth muscle actin (a-SMA; catalog #M0851; Dako).
For labeling of CD31, all of the following steps were
performed on an autostainer at room temperature with
Tris-buffered saline and Tween 20 (catalog #TA-999TT;
ThermoShandon, Freemont, CA) buffer rinses between
steps. Enzyme-induced epitope retrieval was done with
proteinase K (10 minutes; catalog #S3020; Dako). Sections
were incubated with anti-CD31 antibody at 1:20 for
60 minutes and then with the secondary biotinylated rabbit
anti-rat antibody (Vector; catalog #BA-4001; Burlingame,
CA) at 1:200 for 10 minutes. For the labeling of a-SMA, the
primary antibody was ﬁrst biotinylated with the ARK kit
(catalog #K3954; Dako) according to the manufacturer’s
instructions. Heat-induced epitope retrieval was performed
in a decloaking chamber with citrate buffer, pH 6, for 30
minutes at 98C (Invitrogen, Carlsbad, CA; catalog #00-
5000). Sections were incubated with the biotinylated primary
antibody for 30 minutes. Bound antibodies were detected
with the horseradish peroxidase-labeled streptavidin method
(catalog #TS-125-HR; ThermoShandon), with 3,30-di-
aminobenzidine (catalog #TA-125-HDX; ThermoShandon)
as chromogenic substrate (DAB; catalog #TA-125-HDX;
ThermoShandon). Sections were counterstained with May-
er’s hematoxylin (catalog #TA-125-MH; ThermoShandon).
Results
Overall, 34.2% (88 of 257) of BALBcJ and 16.0% (30 of
188; P < 0.0001) of BALBcAnN mice developed ON of the
distal femoral epiphysis, characterized by necrotic bone
marrow adipose tissue and hematopoietic cells, ghost oste-
ocytes, and empty osteocyte lacunae within trabecular bone
[Figure 1, B and D (compare with control in Figure 1, A andajp.amjpathol.org - The American Journal of Pathology







no. (%) P value*
BALBcAnN
DEX 4 mg (n Z 56) 0.21
Positive ON 3 (5.4) 1 1 (100) 0 (0)
Negative ON 53 (94.6) 13 2 (15.4) 11 (84.6)
DEX 4 mg þ ASP (n Z 19) 0.17
Positive ON 2 (10.5) 2 2 (100) 0 (0)
Negative ON 17 (89.5) 2 0 (0) 2 (100)
DEX 8 mg (n Z 54) 0.0002
Positive ON 17 (31.5) 12 12 (100) 0 (0)
Negative ON 37 (68.5) 16 5 (31.3) 11 (68.8)
DEX 8 mg þ ASP (n Z 59) 0.02
Positive ON 8 (13.6) 8 7 (87.5) 1 (12.5)
Negative ON 51 (86.4) 8 2 (25.0) 6 (75.0)
BALBcAnN total (n Z 188) <0.0001
Positive ON 30 (16.0) 23 22 (95.7) 1 (4.3)
Negative ON 158 (84.0) 39 9 (23.1) 30 (76.9)
BALBcJ
DEX 4 mg (n Z 137) <0.0001
Positive ON 43 (31.4) 29 29 (100) 0 (0)
Negative ON 94 (68.6) 21 11 (52.4) 10 (47.6)
DEX þ 6MP (n Z 99) <0.0001
Positive ON 38 (38.4) 35 35 (100) 0 (0)
Negative ON 61 (61.6) 25 13 (52.0) 12 (48.0)
DEX 4 mg þ ASP (n Z 21) 0.14
Positive ON 7 (33.3) 4 4 (100) 0 (0)
Negative ON 14 (66.7) 3 1 (33.3) 2 (66.7)
BALB/cJ total (n Z 257) <0.0001
Positive ON 88 (34.2) 68 68 (100) 0 (0)
Negative ON 169 (65.8) 49 25 (51.0) 24 (49.0)
All Mice
(n Z 445) <0.0001
Positive ON 118 (26.5) 91 90 (98.9) 1 (1.1)
Negative ON 327 (73.5) 88 34 (38.6) 54 (61.4)
*P values for comparing the incidence of arteriopathy in ON-positive and ON-negative cases, using c2 test (if the expected number of cases in each category
is 5) or Fisher’s exact test (if the expected number of cases in any category is <5).
ASP, asparaginase; 6-MP, 6-mercaptopurine.
Arteriopathy in Steroid-Induced ONC)]; we have previously reported on the substrain difference
in occurrence of ON.7 An arteriolar branch of the medial
genicular artery coursing along the dorsal surface of the
distal femur was detected in 40.2% (179 of 445) of the mice.
Lesions were present in the vessels of 98.9% (90 of 91) of
mice with ON and in 38.6% (34 of 88; P < 0.0001) of mice
without ON [Figure 1F (compare with control in Figure 1E)
and Table 1], indicating that arteriopathy was associated
with the occurrence of ON and that vascular lesions could be
detected in mice who had no signs of ON. In the one mouse
with ON that was negative for vascular lesions, the area of
necrosis was <10% of the epiphysis, and it is possible that,
although an unaffected vessel was present in the section, the
unaffected vessel was in a different plane of section.
The mildest vascular lesions were observed in eight mice
without ON and included loss of endothelium, necrosis ofThe American Journal of Pathology - ajp.amjpathol.orgvascular smooth muscle cells, and thickening and basophilia
of the vessel wall (Figure 2A). When stained with trichrome
(Figure 2B), loss of trichrome-positive staining was
observed in the thickened area of the vascular wall, perhaps
indicating loss of protein because of necrosis of smooth
muscle cells. Supporting this conclusion was the loss of a-
SMA (Figure 2C), and loss of endothelial CD31 labeling
(Figure 2D) in the affected areas. It should be noted that at
this stage these changes in the vessel wall were present
without evidence of luminal obstruction (Figure 3A). In
some mice, these lesions progressed to transmural necrosis
and thickening of the vessel wall, fragmentation of the
internal elastic lamina, and mural thickening to the point of
luminal occlusion (Figure 3B). Elastin histochemistry
clearly showed the fragmentation of the internal elastic
lamina in the involved sites (Figure 3, C and D). At this21
Figure 1 H&E-stained sagittal sections of the distal femoral epiphysis,
physis, and metaphysis in control (A, C, and E) and ON (B, D, and F) mice.
Location of vessels supplying the epiphysis is indicated in A and B by an
arrow. A: Normal marrow and trabecular bone. B: Steroid-induced severe
ON, diffusely necrotic epiphyseal marrow, and trabecular bone. C: Magni-
ﬁcation of boxed area in A shows healthy osteocytes within lacunae and
normal hematopoietic cells. D: Magniﬁcation of boxed area in B shows loss
of osteocytes within lacunae and necrotic bone marrow. E: Normal trans-
cortical arteriole. F: Degeneration, necrosis, and luminal occlusion of
transcortical arteriole in mouse with ON. Original magniﬁcation: 40
(A and B); 400 (C and D); 600 (E and F).
Janke et alstage, there was generally only localized necrosis of the bone
marrow in the femoral epiphysis and only rare empty oste-
ocyte lacunae. In some vessels, thrombi developed proximal
to areas of vascular occlusion (Figure 3, E and F); at this
stage often more extensive marrow necrosis was accompa-
nied by occasional empty osteocyte lacunae. In the most
severe and advanced cases of ON, end-stage lesions consisted
of fully occluded vessels with marrow and bone necrosis that
involved the entire epiphysis (Figure 3, G and H).Figure 2 Mildest visible lesion in arterioles supplying the distal femoral
epiphysis in steroid-treated mice. A: H&E staining shows segmental mild
thickening of vessel wall, increased basophilia, and loss of smooth muscle cell
and endothelial cell nuclei in area indicated by arrow. B: Masson’s trichrome,
segmental loss of trichrome-positive staining in area of vascular smooth
muscle cells. Segment indicated by arrow. C: a-SMA immunohistochemistry
shows loss of a-SMA in area of smooth muscle necrosis. Segment indicated by
arrow. D: CD31 immunohistochemistry shows segmental loss of endothelial
cells. Area indicated by the arrow. Original magniﬁcation: 600 (AeD).Discussion
We observed that an arteriopathy involving branches of the
medial genicular artery supplying the distal femoral epiph-
ysis preceded the development of ON. The mildest vascular
lesions are characterized by loss of endothelium and
necrosis of arterial smooth muscle, and more severe lesions
include transmural necrosis of the vessel wall, luminal
occlusion, and proximal thrombosis. It is our hypothesis that22these mild, moderate, and severe lesions indicate progres-
sive stages in the generation of ON. Our ﬁndings clearly
indicate that these vascular lesions can exist without the
characteristic bone lesions of ON in the epiphyseal marrow
and trabecular bone, which include marrow necrosis, edema,
and loss of osteocytes. Because of the small size of the
branches of the medial genicular artery and the method of
sectioning, the blood vessels were not present in all sections
analyzed, but it is presumed that, given more extensive
sampling of the bones, all of those with ON would have
concomitant vascular lesions.
The pattern and extent of lesions present in the blood
vessels, marrow, and bone suggest that occlusion of the
vasculature supplying one portion of the epiphysis, resulting
in marrow with or without bone necrosis in a focal area,
initiates a cascade of events within the epiphysis that results
in complete necrosis. It is likely that focal necrosis in one
part of the femoral epiphysis can initiate edema and in-
ﬂammation in the conﬁned space of epiphyseal marrow that
results in a compartment syndrome that compromises local
blood ﬂow. The hypothesis that increased intramedullary
pressure leads to ON was ﬁrst proposed by Arlet et al8 in
1972, although the mechanism and sequence of events theyajp.amjpathol.org - The American Journal of Pathology
Figure 3 Vascular lesions in arterioles supplying the distal femoral
epiphysis. A: H&E staining of cross-section of arteriole shows transmural
necrosis and the absence of intraluminal obstruction. B: H&E staining of
cross-section of arteriole shows transmural necrosis, thickening of the
vessel wall, and partial luminal obstruction. C: H&E staining shows diffuse
transmural necrosis with segmental thickening of the vessel wall and partial
loss of the internal elastic lamina. D: Elastin histochemistry performed after
removal of coverslip and de-staining of section in C, showing seg-
mental loss and discontinuity of the internal elastic lamina, indicated by
arrow. E: H&E staining of sagittal section of distal femoral epiphysis shows
complete occlusion of vascular lumen by a thrombus proximal to the area of
mural thickening (boxed area) and diffuse, extensive bone marrow necrosis
(asterisk) and focal, partial necrosis of trabecular bone. F: Magniﬁcation of
boxed area in E. G: H&E staining of sagittal section of distal femoral
epiphysis, physis, and metaphysis shows thrombosis of segment of vessel
located proximal to the vessel shown in boxed area of E, concurrent with
diffuse, extensive bone marrow and trabecular bone necrosis (asterisk).
H: Magniﬁcation of boxed area in G. Original magniﬁcation: 600 (A);
400 (BeD, F, and H); 100 (E and G).
Arteriopathy in Steroid-Induced ONput forth differs fromwhat we are suggesting here. Arlet et al8
proposed that the process of ON begins with compression of
the intraosseous sinusoidal system, which leads to venous
stasis and eventually to arterial obstruction and subsequent
bone injury. In contrast, our ﬁndings indicate that the initi-
ating event is within the supplying arteries and arterioles and
that the subsequent inﬂammation, edema, and necrosis in the
epiphysis are secondary, self-propagating events.
Interestingly, similar lesions in the arteries and arterioles
supplying the femoral head have been reported in humans.
For example, thickening of the intima and various degrees
of intimal damage were seen in hip capsule arteries in
patients who received a renal transplant who were treatedThe American Journal of Pathology - ajp.amjpathol.orgwith high-dose steroids but showed no overt symptoms of
hip disease before death.9 In another study, Saito et al10
examined core biopsy specimens from femoral heads with
silent ON of the femoral head, advanced ON of the femoral
head, and osteoarthrosis controls. The most consistent ﬁnding
in patients with ON of the femoral head was what was
described by the investigators as an “arteriopathy which
comprised the structural damage to the vascular wall of arte-
rioles and the residue of broken-down blood vessels.”10,p102
The tunica media showed various combinations of degener-
ation, loss of elastin and collagen ﬁbers, disruption of the
internal elastic lamina, and smooth muscle cell necrosis and
loss. Only mild changes in the tunica intima were observed.10
In mice, structural changes similar to those described here
were observed in response to local corticosteroid treatment.
Delivery of DEX to the femoral artery with the use of
a drug-eluting polymer cuff induced dose-dependent me-
dial atrophy, a reduction in vascular smooth muscle cells
and collagen content, and disruption of the internal elastic
lamina.11 Local DEX delivery to arteries has been tested in
other animal models in an attempt to inhibit restenosis, with
inconsistent effects on neointimal hyperplasia; however,
no mention of adverse changes to the medial tissue was
reported.12e14 This may have been due to different con-
centrations of DEX or to species differences in the vascular
delivery of or reactivity to the drug.
In comparing several different strains of mice, we
previously found BALB/c mice to be the most susceptible to
DEX-induced ON.6 The reason for the increased suscepti-
bility in this strain of mice has not been determined, but
several studies have reported that BALB/c mice have fewer
native collateral blood vessels in the hind limb than do mice
of other strains.15e17 In models of hind limb ischemia in-
duced with femoral artery ligation, the reduced collateral
circulation in BALB/c results in greater reduction in per-
fusion immediately after femoral ligation, slower recovery
of perfusion, greater impairment of hind limb use, and more
severe ischemia.16,17 The reduced collateral circulation in
BALB/c mice may explain why they are more prone to
steroid-induced ON. It is possible that other strains of mice
experience similar damage to the supplying arteries and
arterioles but have sufﬁcient collateral circulation to main-
tain perfusion at a high enough level to prevent marrow or
bone necrosis.
Our previous studies showed development of ON in the
distal femur (femoral condyles) but not in the femoral head.6
Most studies that use other animal models of ON, including
those in rats, rabbits, and pigs, have focused on the femoral
head and/or the vessels feeding the femoral head, that is, the
lateral epiphyseal arteries.18,19 It is unknown whether ON
occurs in the femoral condyles in these other animal models,
because these sites do not appear to have been examined.
Importantly, steroid-induced ON in humans results in
necrosis in the distal femur as frequently as in the femoral
head. Sakamoto et al20 reported the incidence of steroid-
induced ON to be 63% in the hip and 51% in the knee,23
Janke et alwhen diagnosed by magnetic resonance image screening. A
more recent screening study found an overall incidence of
ON of 21.5% in patients before bone marrow trans-
plantation, with 11.7% involving the hip and 23.5% the
knee.21 What is common to the skeletal areas more
frequently developing ON, whether at the hip or knee joint,
is the vulnerability of these sites to vascular lesions as
a result of the unique vascular anatomy in those locations;
their nutrient vessels are tortuous and have limited anasto-
moses.22 Analysis of the arterial supply to the distal femur
in humans has shown that the intraosseous supply to the
medial condyle appears to consist of a single nutrient vessel
supplying the subchondral bone with an apparent watershed
area of limited supply.22 In addition, it is likely that
differences in mechanical stress placed on individual vessels
due to variations in areas of greatest weight-bearing inﬂu-
ence which bones ultimately undergo ON.
Other animal models also support a primary role for
vascular dysfunction in the pathogenesis of ON. Spontane-
ously hypertensive rats (SHR), a strain obtained from Wistar
Kyoto rats23 are used as animal models for hypertension and
cerebrovascular disorders, and approximately 50% develop
spontaneous necrosis of the femoral head from 10 to 20
weeks of age.24 Stroke-prone SHR (SHRSP) are rats ob-
tained by selective mating of SHR25; they have a reported
ON incidence of 70% at 10 to 14 weeks of age.26 Notably,
steroid treatment in SHRSP rats potentiates the develop-
ment of ON; 2 weeks after the administration of a 20-mg/kg
intramuscular injection of methylprednisolone in 17-week-
old rats, 95.2% of treated rats exhibited ON compared
with 51.2% of rats in the control group.27 Although the
molecular mechanism underlying the susceptibility of SHR
and SHRSP rats to ON is unknown, these ﬁndings suggest
that it is potentiated by corticosteroids.
Both direct and indirect effects of glucocorticoids have
been proposed to be responsible for vascular damage
leading to ON.5,28 Examinations of the direct pharmaco-
logic effects of corticosteroids on blood vessels supplying
the femoral head have been performed in ON models in
pigs and rabbits. Corticosteroids reduce femoral head blood
ﬂow in pigs,29 have a vasoconstrictive effect on lateral
epiphyseal arteries of the femoral head,30,31 and potentiate
the vasoconstriction elicited by endothelin-1.31 ON of the
femur and humerus was prevented in a rabbit model when
a nitrate skin patch was administered at the same time
as intramuscular administration of methylprednisolone at
20 mg/kg of body weight.32 Glucocorticoid receptors have
been shown in the media of the canine aorta,33 and
numerous in vitro studies have provided evidence that the
glucocorticoid receptor is present in both the vascular
smooth muscle34e36 and the vascular endothelium.35,37,38 In
addition to the expected effect of changes in gene expres-
sion, studies have indicated that they may mediate the effect
of glucocorticoids on the inﬂux of Naþ or Ca2þ into
cells.35,39 It is possible that the same mechanisms regulating
the vasoconstrictive actions of glucocorticoids, and thereby24reduced blood ﬂow, also lead to eventual degeneration and
necrosis of vascular smooth muscle cells and endothelium.
However, the pharmacologic regulation of blood ﬂow to
bone has been shown to differ from that to other organs40;
therefore, the speciﬁc mechanism leading to necrosis of
blood vessels supplying the epiphysis as observed in this
study may be unique.
Our ﬁnding that progressive lesions develop in the arte-
rioles supplying the distal femoral epiphyses before any
abnormalities become evident in the bone or bone marrow
indicates that a primary arteriopathy is the underlying cause
of steroid-induced ON. A better understanding of the origin
and pathogenesis of steroid-induced ON should prove useful
in the development of improved diagnostic and therapeutic
approaches in the prevention and treatment of this disease
process.Acknowledgments
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